Clinical outcomes associated with expression of aurora kinase and p53 family members in muscle‑invasive bladder cancer

Burgess,Earle F.; Livasy,Chad; Trufan,Sally; Zhu,Jason; O'Connor,Hazel F.; Hartman,Aaron; Clark,Peter E.; Grigg,Claud; Raghavan,Derek

doi:10.3892/mco.2022.2535

Clinical outcomes associated with expression of aurora kinase and p53 family members in muscle‑invasive bladder cancer

Authors:
- Earle F. Burgess
- Chad Livasy
- Sally Trufan
- Jason Zhu
- Hazel F. O'Connor
- Aaron Hartman
- Peter E. Clark
- Claud Grigg
- Derek Raghavan
View Affiliations

Affiliations: Department of Solid Tumor Oncology, Levine Cancer Institute, Atrium Health, Charlotte, NC 28204, USA, Carolinas Pathology Group, Charlotte, NC 28203, USA, Department of Cancer Biostatistics, Levine Cancer Institute, Atrium Health, Charlotte, NC 28204, USA, Department of Urology, Levine Cancer Institute, Atrium Health, Charlotte, NC 28204, USA
Published online on: April 8, 2022 https://doi.org/10.3892/mco.2022.2535
Article Number: 102
Copyright: © Burgess et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Biomarkers are needed in muscle‑invasive bladder cancer (MIBC). We previously reported that high tumor aurora kinase (AURK) A expression identifies patients with MIBC with poor prognosis. Aberrant p53 expression has also been associated with poor outcomes in MIBC, though to the best of our knowledge, co‑expression rates of p53 and aurora kinases have not been previously described in MIBC. As aurora kinase and p53 family members may co‑regulate each other, the present study investigated whether tumor p53 or p63 protein expression influenced the prognostic value of AURKA in a pilot study of 50 patients with MIBC treated with curative intent. Immunohistochemistry for AURKA, AURKB, p53 and p63 were performed on archival pre‑treatment tumor specimens and correlated with clinical outcomes in patients with MIBC who received neoadjuvant chemotherapy (NAC) prior to cystectomy. Baseline p53 [hazard ratio (HR) 1.46; 95% confidence interval (CI)=0.55‑3.9; P=0.448) and p63 (HR 2.02; 95% CI=0.51‑8.1; P=0.313) protein expression did not predict for overall survival (OS). Low p53 protein expression did not correlate with high AURKA (φ=0.190) or AURKB (φ=0.075) expression. However, in tumors with low p53 expression (n=17), the presence of either high AURKA or AURKB expression levels predicted an increased risk for relapse (HR 27.1; 95% CI=2.7‑270.1; P=0.005) and mortality (HR 14.9; 95% CI=2.3‑95.6; P=0.004) compared to tumors with both low AURKA and AURKB levels. The relationship between p63 and AURKA/B expression levels was not tested due to the prevalence (80%) of high p63 expression in the present cohort. In tumors with low AURKA expression, p53 status did not predict for OS (HR 0.62; 95% CI 0.2‑3.2; P=0.572). In multivariable analysis, only high baseline AURKA expression predicted for inferior OS (HR 4.9; 95% CI 1.7‑14.1; P=0.003). To the best of our knowledge, the present study was the first to report co‑expression of p53 and aurora kinase family members in MIBC, and although wild‑type p53 may regulate the aurora kinases in preclinical models, the adverse prognostic value of tumor AURKA overexpression was independent from baseline tumor p53 protein expression in the present cohort. AURKA remains an important prognostic biomarker in patients with MIBC and warrants further evaluation in prospective studies to validate whether baseline AURKA can identify patients that are unlikely to benefit from standard of care with NAC.

View Figures

View References

1	Gully CP, Velazquez-Torres G, Shin JH, Fuentes-Mattei E, Wang E, Carlock C, Chen J, Rothenberg D, Adams HP, Choi HH, et al: Aurora B kinase phosphorylates and instigates degradation of p53. Proc Natl Acad Sci USA. 109:E1513–E1522. 2012.PubMed/NCBI View Article : Google Scholar
2	Nikonova AS, Astsaturov I, Serebriiskii IG, Dunbrack RL Jr and Golemis EA: Aurora A kinase (AURKA) in normal and pathological cell division. Cell Mol Life Sci. 70:661–687. 2013.PubMed/NCBI View Article : Google Scholar
3	González-Loyola A, Fernández-Miranda G, Trakala M, Partida D, Samejima K, Ogawa H, Cañamero M, de Martino A, Martínez-Ramírez Á, de Cárcer G, et al: Aurora B overexpression causes aneuploidy and p21Cip1 repression during tumor development. Mol Cell Biol. 35:3566–3578. 2015.PubMed/NCBI View Article : Google Scholar
4	Lin ZZ, Jeng YM, Hu FC, Pan HW, Tsao HW, Lai PL, Lee PH, Cheng AL and Hsu HC: Significance of aurora B overexpression in hepatocellular carcinoma. Aurora B overexpression in HCC. BMC Cancer. 10(461)2010.PubMed/NCBI View Article : Google Scholar
5	Compérat E, Bièche I, Dargère D, Laurendeau I, Vieillefond A, Benoit G, Vidaud M, Camparo P, Capron F, Verret C, et al: Gene expression study of Aurora-A reveals implication during bladder carcinogenesis and increasing values in invasive urothelial cancer. Urology. 72:873–877. 2008.PubMed/NCBI View Article : Google Scholar
6	Lei Y, Yan S, Ming-De L, Na L and Rui-Fa H: Prognostic significance of Aurora-A expression in human bladder cancer. Acta Histochem. 113:514–518. 2011.PubMed/NCBI View Article : Google Scholar
7	Zhang J, Li B, Yang Q, Zhang P and Wang H: Prognostic value of Aurora kinase A (AURKA) expression among solid tumor patients: A systematic review and meta-analysis. Jpn J Clin Oncol. 45:629–636. 2015.PubMed/NCBI View Article : Google Scholar
8	Huang D, Huang Y, Huang Z, Weng J, Zhang S and Gu W: Relation of AURKB over-expression to low survival rate in BCRA and reversine-modulated aurora B kinase in breast cancer cell lines. Cancer Cell Int. 19(166)2019.PubMed/NCBI View Article : Google Scholar
9	Sen S, Zhou H, Zhang RD, Yoon DS, Vakar-Lopez F, Ito S, Jiang F, Johnston D, Grossman HB, Ruifrok AC, et al: Amplification/overexpression of a mitotic kinase gene in human bladder cancer. J Natl Cancer Inst. 94:1320–1329. 2002.PubMed/NCBI View Article : Google Scholar
10	Mobley A, Zhang S, Bondaruk J, Wang Y, Majewski T, Caraway NP, Huang L, Shoshan E, Velazquez-Torres G, Nitti G, et al: Aurora kinase A is a biomarker for bladder cancer detection and contributes to its aggressive behavior. Sci Rep. 7(40714)2017.PubMed/NCBI View Article : Google Scholar
11	Yu J, Zhou J, Xu F, Bai W and Zhang W: High expression of aurora-B is correlated with poor prognosis and drug resistance in non-small cell lung cancer. Int J Biol Markers. 33:215–221. 2018.PubMed/NCBI View Article : Google Scholar
12	Liu Q, Kaneko S, Yang L, Feldman RI, Nicosia SV, Chen J and Cheng JQ: Aurora-A abrogation of p53 DNA binding and transactivation activity by phosphorylation of serine 215. J Biol Chem. 279:52175–52182. 2004.PubMed/NCBI View Article : Google Scholar
13	Burgess EF, Livasy C, Trufan S, Hartman A, Guerreri R, Naso C, Clark PE, Grigg C, Symanowski J and Raghavan D: High aurora kinase expression identifies patients with muscle-invasive bladder cancer who have poor survival after neoadjuvant chemotherapy. Urol Oncol. 37:900–906. 2019.PubMed/NCBI View Article : Google Scholar
14	Sasai K, Treekitkarnmongkol W, Kai K, Katayama H and Sen S: Functional significance of aurora kinases-p53 protein family interactions in cancer. Front Oncol. 6(247)2016.PubMed/NCBI View Article : Google Scholar
15	Robertson AG, Kim J, Al-Ahmadie H, Bellmunt J, Guo G, Cherniack AD, Hinoue T, Laird PW, Hoadley KA, Akbani R, et al: Comprehensive molecular characterization of muscle-invasive bladder cancer. Cell. 171:540–556.e25. 2017.PubMed/NCBI View Article : Google Scholar
16	Esrig D, Spruck CH III, Nichols PW, Chaiwun B, Steven K, Groshen S, Chen SC, Skinner DG, Jones PA and Cote RJ: p53 nuclear protein accumulation correlates with mutations in the p53 gene, tumor grade, and stage in bladder cancer. Am J Pathol. 143:1389–1397. 1993.PubMed/NCBI
17	George B, Datar RH, Wu L, Cai J, Patten N, Beil SJ, Groshen S, Stein J, Skinner D, Jones PA and Cote RJ: p53 gene and protein status: The role of p53 alterations in predicting outcome in patients with bladder cancer. J Clin Oncol. 25:5352–5358. 2007.PubMed/NCBI View Article : Google Scholar
18	Esrig D, Elmajian D, Groshen S, Freeman JA, Stein JP, Chen SC, Nichols PW, Skinner DG, Jones PA and Cote RJ: Accumulation of nuclear p53 and tumor progression in bladder cancer. N Engl J Med. 331:1259–1264. 1994.PubMed/NCBI View Article : Google Scholar
19	Garcia del Muro X, Condom E, Vigués F, Castellsagué X, Figueras A, Muñoz J, Solá J, Soler T, Capellà G and Germà JR: p53 and p21 expression levels predict organ preservation and survival in invasive bladder carcinoma treated with a combined-modality approach. Cancer. 100:1859–1867. 2004.PubMed/NCBI View Article : Google Scholar
20	Shariat SF, Tokunaga H, Zhou J, Kim J, Ayala GE, Benedict WF and Lerner SP: p53, p21, pRB, and p16 expression predict clinical outcome in cystectomy with bladder cancer. J Clin Oncol. 22:1014–1024. 2004.PubMed/NCBI View Article : Google Scholar
21	Stadler WM, Lerner SP, Groshen S, Stein JP, Shi SR, Raghavan D, Esrig D, Steinberg G, Wood D, Klotz L, et al: Phase III study of molecularly targeted adjuvant therapy in locally advanced urothelial cancer of the bladder based on p53 status. J Clin Oncol. 29:3443–3449. 2011.PubMed/NCBI View Article : Google Scholar
22	Katayama H, Sasai K, Kawai H, Yuan ZM, Bondaruk J, Suzuki F, Fujii S, Arlinghaus RB, Czerniak BA and Sen S: Phosphorylation by aurora kinase A induces Mdm2-mediated destabilization and inhibition of p53. Nat Genet. 36:55–62. 2004.PubMed/NCBI View Article : Google Scholar
23	Yang TY, Teng CJ, Lin TC, Chen KC, Hsu SL and Wu CC: Transcriptional repression of aurora-A gene by wild-type p53 through directly binding to its promoter with histone deacetylase 1 and mSin3a. Int J Cancer. 142:92–108. 2018.PubMed/NCBI View Article : Google Scholar
24	Shao S, Wang Y, Jin S, Song Y, Wang X, Fan W, Zhao Z, Fu M, Tong T, Dong L, et al: Gadd45a interacts with aurora-A and inhibits its kinase activity. J Biol Chem. 281:28943–28950. 2006.PubMed/NCBI View Article : Google Scholar
25	Li Z, Sun Y, Chen X, Squires J, Nowroozizadeh B, Liang C and Huang J: p53 mutation directs AURKA overexpression via miR-25 and FBXW7 in prostatic small cell neuroendocrine carcinoma. Mol Cancer Res. 13:584–591. 2015.PubMed/NCBI View Article : Google Scholar
26	Teng CL, Hsieh YC, Phan L, Shin J, Gully C, Velazquez-Torres G, Skerl S, Yeung SC, Hsu SL and Lee MH: FBXW7 is involved in aurora B degradation. Cell Cycle. 11:4059–4068. 2012.PubMed/NCBI View Article : Google Scholar
27	Yang A and McKeon F: P63 and P73: P53 mimics, menaces and more. Nat Rev Mol Cell Biol. 1:199–207. 2000.PubMed/NCBI View Article : Google Scholar
28	Katayama H, Wang J, Treekitkarnmongkol W, Kawai H, Sasai K, Zhang H, Wang H, Adams HP, Jiang S, Chakraborty SN, et al: Aurora kinase-A inactivates DNA damage-induced apoptosis and spindle assembly checkpoint response functions of p73. Cancer Cell. 21:196–211. 2012.PubMed/NCBI View Article : Google Scholar
29	Gailey MP and Bellizzi AM: Immunohistochemistry for the novel markers glypican 3, PAX8, and p40 (ΔNp63) in squamous cell and urothelial carcinoma. Am J Clin Pathol. 140:872–880. 2013.PubMed/NCBI View Article : Google Scholar
30	Karni-Schmidt O, Castillo-Martin M, Shen TH, Gladoun N, Domingo-Domenech J, Sanchez-Carbayo M, Li Y, Lowe S, Prives C and Cordon-Cardo C: Distinct expression profiles of p63 variants during urothelial development and bladder cancer progression. Am J Pathol. 178:1350–1360. 2011.PubMed/NCBI View Article : Google Scholar
31	Park BJ, Lee SJ, Kim JI, Lee SJ, Lee CH, Chang SG, Park JH and Chi SG: Frequent alteration of p63 expression in human primary bladder carcinomas. Cancer Res. 60:3370–3374. 2000.PubMed/NCBI
32	Cao X, Hou J, An Q, Assaraf YG and Wang X: Towards the overcoming of anticancer drug resistance mediated by p53 mutations. Drug Resist Updat. 49(100671)2020.PubMed/NCBI View Article : Google Scholar
33	He S, Feng M, Liu M, Yang S, Yan S, Zhang W, Wang Z, Hu C, Xu Q, Chen L, et al: P21-activated kinase 7 mediates cisplatin-resistance of esophageal squamous carcinoma cells with aurora-A overexpression. PLoS One. 9(e113989)2014.PubMed/NCBI View Article : Google Scholar
34	Bunch B, Krishnan N, Greenspan RD, Ramakrishnan S, Attwood K, Yan L, Qi Q, Wang D, Morrison C, Omilian A, et al: TAp73 expression and P1 promoter methylation, a potential marker for chemoresponsiveness to cisplatin therapy and survival in muscle-invasive bladder cancer (MIBC). Cell Cycle. 18:2055–2066. 2019.PubMed/NCBI View Article : Google Scholar
35	Puig P, Capodieci P, Drobnjak M, Verbel D, Prives C, Cordon-Cardo C and Di Como CJ: p73 expression in human normal and tumor tissues: loss of p73alpha expression is associated with tumor progression in bladder cancer. Clin Cancer Res. 9:5642–5651. 2003.PubMed/NCBI
36	Seiler R, Ashab HAD, Erho N, van Rhijn BWG, Winters B, Douglas J, Van Kessel KE, Fransen van de Putte EE, Sommerlad M, Wang NQ, et al: Impact of molecular subtypes in muscle-invasive bladder cancer on predicting response and survival after neoadjuvant chemotherapy. Eur Urol. 72:544–554. 2017.PubMed/NCBI View Article : Google Scholar
37	Necchi A, Lo Vullo S, Mariani L, Raggi D, Giannatempo P, Calareso G, Togliardi E, Crippa F, Di Genova N, Perrone F, et al: An open-label, single-arm, phase 2 study of the aurora kinase A inhibitor alisertib in patients with advanced urothelial cancer. Invest New Drugs. 34:236–242. 2016.PubMed/NCBI View Article : Google Scholar
38	Dar AA, Belkhiri A, Ecsedy J, Zaika A and El-Rifai W: Aurora kinase A inhibition leads to p73-dependent apoptosis in p53-deficient cancer cells. Cancer Res. 68:8998–9004. 2008.PubMed/NCBI View Article : Google Scholar
39	Tentler JJ, Ionkina AA, Tan AC, Newton TP, Pitts TM, Glogowska MJ, Kabos P, Sartorius CA, Sullivan KD, Espinosa JM, et al: p53 family members regulate phenotypic response to aurora kinase A inhibition in triple-negative breast cancer. Mol Cancer Ther. 14:1117–1129. 2015.PubMed/NCBI View Article : Google Scholar
40	Grossman HB, Natale RB, Tangen CM, Speights VO, Vogelzang NJ, Trump DL, deVere White RW, Sarosdy MF, Wood DP Jr, Raghavan D and Crawford ED: Neoadjuvant chemotherapy plus cystectomy compared with cystectomy alone for locally advanced bladder cancer. N Engl J Med. 349:859–866. 2003.PubMed/NCBI View Article : Google Scholar